Mar 9, 20211 min
$CYDY -28% Announced mix data in critically ill COVID-19 patients receiving Leronlimab PRO 140. They also announced plans to file accelerated rolling review with MHRA source
$CARA -1% NDA acceptance of Korsuva injection in hemodialysis patients with moderate-to-severe pruritus. source
$MCRB -7% Discontinues enrollment in SER-401 study in metastatic melanoma. Discontinuation due to difficulty enrolling due to COVID-19, company focusing on other pipeline assets and deprioritizes SER-401. source
$SESN +1% Submits MAA to EMA for Vicineum for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). source
$ANAB -34% Announced that it's phase 2 trial of imsidolimab for the treatment of moderate-to-severe palmoplantar pustulosis (PPP), also known as POPLAR trial, failed to meet it's primary endpoints. source
$SLNO -49% Following the Type C meeting with the FDA regarding DCCR, they informed the company an additional controlled clinical trial will be necessary to support an NDA submission. source
$XENE -1% IND acceptance for a phase 2 trial of XEN1101 in major depressive disorder (MDD) set to initiate in Q2 2021. source